TRIP13 and Miyoshi myopathy: Our studies showed that, TI17, a novel small molecular, effectively exert antitumor activity on MM by impairing Trip13 function of DSBs repair and enhancing DNA damage responses via inhibition of MM cells proliferation, accumulation of MM cells at G0/G1 phase, induction of MM cells apoptosis, and retardation of tumor growth in vivo.